Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120666 | 1.00 | OPRL1 (0.40) | OPRL1SLC18A3NPSR1LMNATP53 | |
| SCHEMBL4120669 | 1.00 | OPRL1 (0.40) | OPRL1SLC18A3NPSR1LMNATP53 | |
| SCHEMBL4122366 | 1.00 | OPRL1 (0.40) | OPRL1SLC18A3NPSR1LMNATP53 | |
| SCHEMBL4120673 | 1.00 | OPRL1 (0.40) | OPRL1SLC18A3NPSR1LMNATP53 | |
| SCHEMBL4137839 | 0.87 | HTR2B (0.43) | SLC18A3NPSR1LMNATP53TSHR | |
| SCHEMBL4137837 | 0.87 | HTR2B (0.43) | SLC18A3NPSR1LMNATP53TSHR | |
| SCHEMBL4137845 | 0.87 | HTR2B (0.43) | SLC18A3NPSR1LMNATP53TSHR | |
| SCHEMBL4119746 | 0.83 | ADRA2A (0.37) | LMNATP53TSHRALDH1A1 | |
| SCHEMBL4119739 | 0.83 | ADRA2A (0.37) | LMNATP53TSHRALDH1A1 | |
| SCHEMBL4119743 | 0.83 | ADRA2A (0.37) | LMNATP53TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075982-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | disclosed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075982-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | OPRL1 24/4885SLC18A3 508/4885NPSR1 25/4885 |
| US-20090076030-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | OPRL1 24/4885SLC18A3 508/4885NPSR1 25/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | OPRL1 24/4885SLC18A3 508/4885NPSR1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.